1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210
2. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL et al. Edoxaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine. 2013;369(22):2093–104. DOI: 10.1056/NEJMoa1310907
3. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal. 2018;39(16):1330– 93. DOI: 10.1093/eurheartj/ehy136
4. Bergmark BA, Kamphuisen PW, Wiviott SD, Ruff CT, Antman EM, Nordio F et al. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Circulation. 2019;140(22):1792– 801. DOI: 10.1161/CIRCULATIONAHA.119.041346
5. Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016;134(1):24–36. DOI: 10.1161/CIRCULATIONAHA.116.022361
6. Nicolau AM, Corbalan R, Nicolau JC, Ruff CT, Zierhut W, Kerschnitzki M et al. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. European Heart Journal - Cardiovascular Pharmacotherapy. 2020;6(3):167–75. DOI: 10.1093/ehjcvp/pvz061
7. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y et al. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling. Journal of the American College of Cardiology. 2016;68(11):1169–78. DOI: 10.1016/j.jacc.2016.06.034
8. De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF et al. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. Journal of the American College of Cardiology. 2017;69(11):1372–82. DOI: 10.1016/j.jacc.2016.12.031
9. Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M et al. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation. 2017;135(13):1273–5. DOI: 10.1161/CIRCULATIONAHA.116.026714
10. Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT et al. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. Journal of the American College of Cardiology. 2019;74(2):179–89. DOI: 10.1016/j.jacc.2019.04.061
11. Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. The Lancet. 2015;385(9984):2280–7. DOI: 10.1016/S0140-6736(14)61994-2
